Author: Kevin Grogan

The European Commission has given the green light to Chiesi’s Holoclar – which the Italian company says is the first stem-cell therapy to be approved in the western world – for a rare eye condition.

The National Institute for Health and Care Excellence has recommended Bayer’s Eylea as an option for diabetic macular oedema in preliminary recommendations, having agreed a discount with the company.

Sanofi has confirmed that Bayer healthcare boss Olivier Brandicourt is to be its new chief executive, filling the void created by the sacking of Chris Viehbacher in October.

The NHS is paying too high a price for new medicines and the Cancer Drugs Fund represents particularly poor value.

The US Food and Drug Administration has granted a priority review for Roche’s cobimetinib in combination with the company’s already-marketed melanoma drug Zelboraf.